04/11/23 112.10. 09 www.revitalvision.com
04/11/23 112.10.2009 www.revitalvision.com
04/11/23 112.10. 09 www.revitalvision.com
04/11/23 1www.revitalvision.com
TECHNOLOGY & CLINICAL SUMMARY
[24.Feb.2010]
Daniel S. Durrie, MD
Overland Park, Kansas, USA
04/11/23 212.10. 09 www.revitalvision.com
04/11/23 212.10.2009 www.revitalvision.com
04/11/23 212.10. 09 www.revitalvision.com
04/11/23 2www.revitalvision.com
COMPANY OVERVIEW
RevitalVision represents a new category in vision improvement
Non-invasive technology that enhances eyesight neurologically
The company's U.S. launch is focused on improving outcomes after intraocular lens implantation and refractive surgery
Average improvement of 2 lines visual acuity 100% in contrast sensitivity
04/11/23 312.10. 09 www.revitalvision.com
04/11/23 312.10.2009 www.revitalvision.com
04/11/23 312.10. 09 www.revitalvision.com
04/11/23 3www.revitalvision.com
COMPANY OVERVIEW
This computer-based neural vision therapy (NVT) is clinically and scientifically proven to improve the vision outcomes for: Amblyopia post-cataract post-refractive (LASIK) presbyopia night vision low myopes sports vision patients Low Vision
04/11/23 412.10. 09 www.revitalvision.com
04/11/23 412.10.2009 www.revitalvision.com
04/11/23 412.10. 09 www.revitalvision.com
04/11/23 4www.revitalvision.com
HISTORY OF REVITALVISION
The NVT technology was originally developed in Israel where the company was established in 1999.
US FDA 510(K) approval given in August 2001 for the treatment of adult amblyopia (age 9-55).
The company, relocated to Singapore in 2004 under the company name NeuroVision, Inc. due to government interest in the treatment of pediatric
myopia in the Asian Pacific Region.
04/11/23 512.10. 09 www.revitalvision.com
04/11/23 512.10.2009 www.revitalvision.com
04/11/23 512.10. 09 www.revitalvision.com
04/11/23 5www.revitalvision.com
HISTORY OF REVITALVISION
Has treated more than 4,000 patients in Europe, the U.S., and Asia.
In 2009, NeuroVision was purchased by RevitalVision LLC, and operations were relocated to the United States, in Lawrence, Kansas.
The technology has successfully conducted U.S. clinical trials that replicate the international results.
04/11/23 612.10. 09 www.revitalvision.com
04/11/23 612.10.2009 www.revitalvision.com
04/11/23 612.10. 09 www.revitalvision.com
04/11/23 6www.revitalvision.com
RevitalVision Concept
RevitalVision optimizes the visual processing in the brain
Neurologically Retrains the Brain to See Better
VISION = OPTICS (EYE)
+ NEURAL (BRAIN)
+
Vision aids like Spectacles and contact lenses
NeuroVision
04/11/23 712.10. 09 www.revitalvision.com
04/11/23 712.10.2009 www.revitalvision.com
04/11/23 712.10. 09 www.revitalvision.com
04/11/23 7www.revitalvision.com
PRESENT PRODUCT OFFERINGS IN THE USA
PRODUCTS READY FOR MARKET:Amblyopia, Low Vision (Macular Degeneration), Low Myopia, Sports Vision,
Night Driving
04/11/23 812.10. 09 www.revitalvision.com
04/11/23 812.10.2009 www.revitalvision.com
04/11/23 812.10. 09 www.revitalvision.com
04/11/23 8www.revitalvision.com
SCIENTIFIC PREMISE
Software-based, interactive system tailored and continuously adaptive to individual visual abilities
Probes specific neuronal interactions to induce improvement of contrast sensitivity function (CSF) due to a reduction of noise and increase in signal strength
Compensates for blurred inputs coming from the retina by enhancing neural processing
04/11/23 912.10. 09 www.revitalvision.com
04/11/23 912.10.2009 www.revitalvision.com
04/11/23 912.10. 09 www.revitalvision.com
04/11/23 9www.revitalvision.com
SCIENTIFIC BUILDING BLOCKS
Neuronal lateral interactions
Gabor patch visual stimulus
Use of flankers
Perceptual learning
Brain plasticity
04/11/23 1012.10. 09 www.revitalvision.com
04/11/23 1012.10.2009 www.revitalvision.com
04/11/23 1012.10. 09 www.revitalvision.com
04/11/23 10www.revitalvision.com
NEURONAL LATERAL INTERACTIONS
Individual neurons respond to: Precise location Orientation Spatial frequency
Neuronal Interactions: Result in excitation or
suppression Occur at multiple levels of
the visual pathway RevitalVision enhances
these lateral interactions
04/11/23 1112.10. 09 www.revitalvision.com
04/11/23 1112.10.2009 www.revitalvision.com
Gabor Patches developed by Nobel Prize winning physicist, Dennis Gabor
Widely used in the field of visual neuroscience to describe the shape of receptive fields of neurons in the primary visual cortex
They represent the most effective stimulation of the primary visual cortex
GABOR PATCH
04/11/23 1212.10. 09 www.revitalvision.com
04/11/23 1212.10.2009 www.revitalvision.com
The software measures the contrast threshold of a Gabor target with the presence of flankers
The patient is exposed to two short displays in succession and the patient identifies which display contains three Gabors
First Display Second Display
Target
Flankers
USE OF FLANKERS
04/11/23 1312.10. 09 www.revitalvision.com
04/11/23 1312.10.2009 www.revitalvision.com
Lateral masking and collinear alignment of the Gabor patches improve neuronal efficiency and improvement of CSF by reducing the noise to signal ratio of neural activity in the primary visual cortex.
Animal model showed increased visual cortex stimulation with collinearly oriented flankers (spatial frequency patterns are oriented in a linear fasion).1
1. Polat, et al. Collinear stimuli regulate visual responses depending on cell's contrast threshold. Nature. 1998;391: 580-4.
SCIENTIFIC BASIS OF FLANKERS & COLLINEARITY
04/11/23 1412.10. 09 www.revitalvision.com
04/11/23 1412.10.2009 www.revitalvision.com
Spatial Frequency
Local Orientation
Contrast
Target-Flankers Separation
Target Displacement
Global Orientation
MANIPULATION OF GABOR STIMULUS & FLANKERS
04/11/23 1512.10. 09 www.revitalvision.com
04/11/23 1512.10.2009 www.revitalvision.com
Neural plasticity relates to the ability of the nervous system to adapt to changed conditions
Visual acuity improvement in adults with amblyopia has been reported After prolonged patching After the better eye’s vision has been degraded by age
related macular degeneration, cataract or trauma
BRAIN PLASTICITY
04/11/23 1612.10. 09 www.revitalvision.com
04/11/23 1612.10.2009 www.revitalvision.com
The brain pools responses across many neurons to average out noisy activity of single cells improving signal-to-noise ratio, leading to improved visual
performance and acuity
The noise of individual neurons can be brought under experimental control by appropriate choice of stimulus conditions
Contrast sensitivity at low levels can be increased dramatically through control of stimulus parameters
NEUROPROCESSING BASICS
04/11/23 1712.10. 09 www.revitalvision.com
04/11/23 1712.10.2009 www.revitalvision.com
Hubel et al., Receptive fields of single neurons in the cat’s striate cortex. J Physiol 1959,148:574-591
Changes in electrical activity in a cat cortex were examined in response to visual stimulation
Specific neurons in the primary visual cortex respond to specific visual stimulations
The main parameters are location, orientation and spatial frequency of the visual stimulus.
In 1981 Hubel & Wiesel received Nobel Prize for this discovery, which led to understanding of visual processing
NEUROPROCESSING BASICS
04/11/23 1812.10. 09 www.revitalvision.com
04/11/23 1812.10.2009 www.revitalvision.com
Polat, et al. Collinear stimuli regulate visual responses depending on cell's contrast threshold.
Nature. 1998;391: 580-4.
Demonstrated a direct correlation between different contrast levels and single neuron response in the primary visual cortex
There is neural plasticity in the adult brain Perceptual learning can be modified
Vision can improve by perceptual learning technique by practicing a series of controlled and repetitive specific visual tasks.
The vision improvement reflects improved contrast sensitivity.
NEUROPROCESSING BASICS
04/11/23 1912.10. 09 www.revitalvision.com
04/11/23 1912.10.2009 www.revitalvision.com
04/11/23 1912.10. 09 www.revitalvision.com
04/11/23 19www.revitalvision.com
CLINICAL IMPLEMENTATION
Results sent to server. Sessions adjust to
progress, improving neural performance
Results sent to server. Sessions adjust to
progress, improving neural performance
TREATMENT FLOW
04/11/23 2012.10. 09 www.revitalvision.com
04/11/23 2012.10.2009 www.revitalvision.com
After an Orientation Session the patient undergoes two computerized Evaluation Sessions
The Computerized Evaluation sessions identify the patient’s specific visual abilities and inefficiencies and define individual parameters that will affect the patient’s treatment plan
COMPUTERIZED EVALUATION SESSIONS
04/11/23 2112.10. 09 www.revitalvision.com
04/11/23 2112.10.2009 www.revitalvision.com
Typically patient should undergo 30 sessions during this phase (40 for amblyopia).
The patient should perform on average three (3) treatment sessions per week.
Visit interruptions longer than two (2) weeks on aggregate are discouraged.
Three (3) periodic examination are recommended along the treatment sessions to monitor and feedback patient progress.
Amblyopic patients – should prescribed best corrected eyewear before baseline examination, and instructed to wear glasses/contact lenses through the entire treatment period.
In non amblyopic patients - as progress is made, the refraction of the training glasses (previously prescribed to the patient) might change.
04/11/23 2212.10. 09 www.revitalvision.com
04/11/23 2212.10.2009 www.revitalvision.com
Patient will terminate the treatment sequence after 30 sessions (40 for Amblyopia)
Following the end of treatment, the patient should be scheduled for End of Treatment examination
The End of Treatment Examination is a repetition of the Baseline examination
04/11/23 2312.10. 09 www.revitalvision.com
04/11/23 2312.10.2009 www.revitalvision.com
Motivation, consistency and compliance are key for achieving best results
Make your best efforts to concentrate and achieve the best performance during each session
Perform RevitalVision sessions at the time of day you are most alert (Not late night when sleepy)
Perform RevitalVision sessions 3 times a week
Be aware of the quality of your vision throughout the course of treatment. Experience your vision improvement during daily activities
Use your glasses less as vision improves (non amblyopic)
04/11/23 2412.10. 09 www.revitalvision.com
04/11/23 2412.10.2009 www.revitalvision.com
Polat U, Naim TM, Belkin M, Sagi D. PNAS 2004;101:17:6692-6697.
Polat et al. studied 54 adult amblyopic patients who were randomized to amblyopic NVT treatment or a placebo vision-training program.
Pre treatment visual acuity in both study arms was 0.42 logMAR, and this improved by 2.5 lines to 20/30 in the NVT treatment group, with no improvement in the control group. (statistically significant )
This increase in acuity was corroborated by a commensurate increase in CSF to within the normal range.
These improvements in acuity and CSF were sustained after 12 months.
04/11/23 2512.10. 09 www.revitalvision.com
04/11/23 2512.10.2009 www.revitalvision.com
Tan D, Fong A. Efficacy of neural vision therapy to enhance contrast sensitivity function and visual acuity in low
myopia. J Cataract Refract Surg. 2008;Apr;34(4):570-7.
D. Tan and A. Fong conducted a randomized controlled trial evaluating the efficacy of NVT in low myopia.
The results showed statistically significant difference in unaided visual acuity between the masked and treatment groups Mean improvement of 2.6 logMar lines of distance uncorrected
visual acuity for low myopes, 2.0 logMar lines near unaided visual acuity for early presbyopes.
Results suggest evidence of efficacy and safety with NVT treatment in improving visual acuity and contrast sensitivity function in adult low myopes.
04/11/23 2612.10. 09 www.revitalvision.com
04/11/23 2612.10.2009 www.revitalvision.com
Durrie D, McMinn PS. Computer-based primary visual cortex training for treatment of low myopia and early presbyopia. Trans Am
Ophthalmol Soc. 2007;105:132-8
D. Durrie and P. McMinn evaluated 11 patients with low myopia (up to -1.75D) and 18 with early presbyopia (up to +2.50D Add) in 2 clinical sites who underwent NVT.
Control group performed only visual examinations Low myopia group
Treatment group achieved a mean improvement of 2.2 logMAR lines in UAVA.
CSF improved at all spatial frequencies. Control patients did not shown any significant change in vision.
Early presbyopia group Mean improvement of 2.2 logMAR lines in near UCDVA. Near UCSF improved at all spatial frequencies. The control patients did not shown any significant change in
vision. Mean refractive error in all groups remained unchanged
after treatment.
04/11/23 2712.10. 09 www.revitalvision.com
04/11/23 2712.10.2009 www.revitalvision.com
Lim KL, Fam HB. NeuroVision treatment for low myopia following LASIK regression. J Refract
Surg. 2006 Apr;22(4):406-8.
Lim et al. reported a single case of NVT for the treatment low myopic regression five years after bilateral myopic LASIK.
The patient improved 2.8 lines in the right eye and 1.6 lines in the left eye following NVT.
04/11/23 2812.10. 09 www.revitalvision.com
04/11/23 2812.10.2009 www.revitalvision.com
Tan D, Fong A 2007, Unpublished Data
Tan et al. reported clinical data for low myopes and presbyopes after completion of the NVT training.
After treatment there was a mean improvement of 2.8 logMar lines in distance UCVA for 55 low myopes
Mean improvement of 1.6 logMar lines in near UCVA for the 41 presbyopes (age 41-55 year old)
The improvements were shown to be retained for at least 12 months.
04/11/23 2912.10. 09 www.revitalvision.com
04/11/23 2912.10.2009 www.revitalvision.com
Durrie, D. Slade, S. 2008 Unpublished data
Waring IV GO, Durrie DS. NeuroLASIK – Can surgeons improve LASIK outcomes by training the visual cortex? Cataract and
Refractive Surgery Today, Aug 2008;52-53. D. Durrie and S. Slade conducted a prospective, randomized, multicenter
placebo controlled study comparing neural vision therapy (NVT) after LASIK (“NeuroLASIK”) to sham treatment (video game) following LASIK in 98 eyes.
Treatment group UCDVA improved 0.8 Snellen lines 79% improvement in contrast sensitivity function (CSF)
Control group UCDVA 0.28 line improvement 52% improvement in CSF
Patients who were worse than 20/20 after LASIK with NVT UCDVA improved 1.56 Snellen lines 90% improvement in CSF
Control group worse than 20/20 after LASIK with sham treatment UCDVA improved 0.34 lines 47% improvement in CSF
The results suggested that patients who had worse vision improved more and that perhaps there is a cortical limit to how much a patient can improve.
04/11/23 3012.10. 09 www.revitalvision.com
04/11/23 3012.10.2009 www.revitalvision.com
Hunkeler J, Lindstrom D. Unpublished Data 2009
J. Hunkeler and D. Lindstrom prospectively evaluated the efficacy of computer based primary NVT in improving vision after aspheric monofocal, multifocal and accommodative Intraocular Lens (IOL) implantation of 5 different IOL styles in 60 eyes.
After CVT, mean improvement in UCDVA and UCNVA for the entire group was 1.3 and 1.0 lines respectively
Mean improvement in distance and near CSF were 223% and 197% respectively.
After CVT, mean improvement in UCDVA and UCNVA were Crystalens accommodative IOL (N=6) was 0.3 and 1.7 Alcon Restor (N=10) was 1.5 and 1.1 AMO ReZoom (N=24) was 1.4 and 0.7 Alcon Acrysof monofocal (N=10) was 1.3 and 0.7 AMO Technis monofocal (N=10) was 1.4 and 1.3 lines respectively.
04/11/23 3112.10. 09 www.revitalvision.com
04/11/23 3112.10.2009 www.revitalvision.com
Adult Amblyopia Trial: 2000-2001
Treatment Group Control Group
Number of subjects 44 10
Average Age 35.0 ± 13.0 38.2 ± 9.4
Mean BCVA in Amblyopic EyeBefore Treatment in logMar
0.41 ± 0.14(20/51)
0.41 ± 0.12(20/51)
Mean BCVA in Amblyopic EyeAfter Treatment in logMar
0.17 ± 0.14(20/30)
0.41 ± 0.12(20/51)
Mean BCVA in Amblyopic Eye1 Year After Treatment in logMar
0.21 ± 0.14(20/33)
N/A
* FDA approved for Adult Amblyopia
04/11/23 3212.10. 09 www.revitalvision.com
04/11/23 3212.10.2009 www.revitalvision.com
Spatial FrequencySpatial Frequency
BCVA=20/30
BCVA=20/33
BCVA=20/51
12 Months Post Treatment
At End of Treatment
Before Treatment Start
Adult Amblyopia Trial: 2000-2001
04/11/23 3312.10. 09 www.revitalvision.com
04/11/23 3312.10.2009 www.revitalvision.com
Low Myopia, Singapore Eye Research Institute, 2003 - 2004
Treatment Group
Number of subjects 20
Average Age 34.0 (16 to 55)
Mean Cycloplegic Spherical Equivalence Before Treatment
-1.08D (0 to -1.75)
Mean Cycloplegic Spherical Equivalence After Treatment
-1.06D (0 to -1.75)
Mean Unaided VABefore Treatment in logMar
0.31 ± 0.03(20/41)
Mean Unaided VAAfter Treatment in logMar
0.10 ± 0.03(20/25)
Mean Unaided VA1 Year After Treatment in logMar
0.12 ± 0.03(20/26)
04/11/23 3412.10. 09 www.revitalvision.com
04/11/23 3412.10.2009 www.revitalvision.com
Spatial FrequencySpatial Frequency
UCVA=20/25
UCVA=20/26
UCVA=20/41
12 Months Post Treatment
At End of Treatment
Before Treatment Start
Low Myopia, Singapore Eye Research Institute 2003 - 2004
04/11/23 3512.10. 09 www.revitalvision.com
04/11/23 3512.10.2009 www.revitalvision.com
Low Myopia and Post Refractive SurgeryCommercial Data, 2004-2005
Low Myopia Post Refractive Surgery
Number of subjects 259 35
Average Age 30 (7-55) 30 (7-55)
Mean Manifest Spherical Equivalence Before Treatment
-1.34D ± 0.03 -1.14D ± 0.11
Mean Manifest Spherical Equivalence After Treatment
-1.20D ± 0.04 -1.09D ± 0.12
Mean Unaided VABefore Treatment in logMar
0.43 ± 0.01(20/54)
0.32 ± 0.03(20/42)
Mean Unaided VAAfter Treatment in logMar
0.17 ± 0.01(20/30)
0.10 ± 0.02(20/25)
Mean Unaided VA1 Year After Treatment in logMar (48 subjects)
0.21 ± 0.01(20/33)
N/A
04/11/23 3612.10. 09 www.revitalvision.com
04/11/23 3612.10.2009 www.revitalvision.com
Low MyopiaPost Refractive Surgery Commercial Data, 2004-2005
Low Myopia Post Refractive Surgery
Spatial FrequencySpatial Frequency
UCVA=20/28
UCVA=20/54
UCVA=20/30
Spatial FrequencySpatial Frequency
UCVA=20/30
UCVA=20/54
UCVA=20/33
Spatial FrequencySpatial Frequency
UCVA=20/25
UCVA=20/44
Spatial FrequencySpatial Frequency
UCVA=20/25
UCVA=20/42
12 Months Post Treatment
At End of Treatment
Before Treatment Start
04/11/23 3712.10. 09 www.revitalvision.com
04/11/23 3712.10.2009 www.revitalvision.com
Presbyopia, European Trial, 2005
Treatment Group
Number of subjects 41
Average Age 46.37 ± 0.52 (41-55)
Mean Near Addition +1.40D ± 0.05D
Mean Unaided VABefore Treatment in logMar
0.33 ± 0.04(20/43)
Mean Unaided VAAfter Treatment in logMar
0.17 ± 0.04(20/29)
04/11/23 3812.10. 09 www.revitalvision.com
04/11/23 3812.10.2009 www.revitalvision.com
Spatial FrequencySpatial Frequency
UCNVA=20/35
UCNVA=20/54
Spatial FrequencySpatial Frequency
UCNVA=20/29
UCNVA=20/43
Presbyopia, European Trial, 2005
12 Months Post Treatment
At End of Treatment
Before Treatment Start
04/11/23 3912.10. 09 www.revitalvision.com
04/11/23 3912.10.2009 www.revitalvision.com
Visual Acuity Improvement
Contrast SensitivityImprovement
Retention of Improvement
1 Year PostTreatment
Main Functional Outcome
Myopia Up to -1.50D
2.6 Lines ETDRS (Distance)
Above 100% in All Frequencies
85% of the Improvement
Decrease Dependency on Spectacles
Presbyopia Up to +1.5D
2.0 Lines ETDRS(Near)
Average Of 100% in All Frequencies
Delay The Need for Reading Glasses
Post Refractive Surgery
2.3 Lines ETDRS(Distance)
Above 100% in All Frequencies
Increased Quality of Functional Vision
Amblyopia 2.5 Lines ETDRS(Distance)
Above 100% in All Frequencies
85% of the Improvement
Increased Quality of Vision, Improved Binocularity
Visual Improvement and Functional Outcome
04/11/23 4012.10. 09 www.revitalvision.com
04/11/23 4012.10.2009 www.revitalvision.com
New Treatment: “Physical Therapy for Vision”
RevitalVision enhance surgical outcomes
Little or no interruption to current practice procedures
It’s as easy as “writing a prescription”
Therapy can be done anytime, post surgery
04/11/23 4112.10. 09 www.revitalvision.com
04/11/23 4112.10.2009 www.revitalvision.com
Cataract and LASIK products can be offered to patients Bundle with surgery Offer premium package Include as part of standard of care (premium practices)
Minimum extra intervention by doctor’s office
Amblyopia: the only clinically proven treatment to improve vision for adult amblyopic patients
Other products: (amblyopia, presbyopia, low myopia, etc.)
Offer to suitable candidates
04/11/23 4212.10. 09 www.revitalvision.com
04/11/23 4212.10.2009 www.revitalvision.com
Therapeutic opportunity for reduced contrast sensitivity as age and cataract surgery contribute to decline in CSF
Empowers the patient to improve their own visual outcomes
Additional tool for patient satisfaction
Make patient’s vision better
Empower patients to improve with their home “physical therapy for vision.”
Minimum changes necessary at practice level
All technical needs are handled by RevitalVision (distributors).
Patient progress monitored by RevitalVison
Potential source for additional revenue for physician practices
04/11/23 4312.10. 09 www.revitalvision.com
04/11/23 4312.10.2009 www.revitalvision.com
Offer RevitalVision at Surgeon Office Bundle with cataract surgery Offer premium package – up charge Include as part of standard of care (premium practices)
Referring Optometrist
Offer RevitalVision to patient at 3 or 6 month follow-up
All Post Surgical Patients
Patient undergo first guided training session at the clinic and the rest are done at home. Any technical issues are handled directly by RevitalVision (local distributors)
04/11/23 4412.10. 09 www.revitalvision.com
04/11/23 4412.10.2009 www.revitalvision.com
Novel approach to improvement in visual function “Physical therapy for vision” Computer based primary cortex vision training
Founded on proprietary cortical visual science therapeutic strategies
Average improvement of 2 lines visual acuity and 100% in contrast sensitivity
Non-invasive and safe
Multiple treatment indications offerings including amblyopia, post IOL implant therapy, post refractive surgery, presbyopia, Low Myopia, Low Vision, Sport Vision.
Future product offerings in development
04/11/23 4512.10. 09 www.revitalvision.com
04/11/23 4512.10.2009 www.revitalvision.com
RevitalVision, LLCwww.revitalvision.com
NeuroVision/RevitalVision distributors:
ISRAEL- Talshir Medical Technologies Ltd.Turkey- NoroVizyon Ltd.
Greece – Vitamia Medical Ltd.